MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202641050245 A) filed by Dr. Latha Kiran Krishna Rajendran, Bangalore, Karnataka, on April 2, for 'ai-enhanced multi-omics framework for discovery of actionable therapeutic targets and resistance biomarkers.'
Inventor(s) include Dr. Latha Kiran Krishna Rajendran.
The application for the patent was published on May 1, under issue no. 18/2026.
According to the abstract released by the Intellectual Property India: "Modern drug discovery and precision oncology face a foundational analytical crisis rooted in the extraordinary biological complexity of disease-driving molecular networks, wherein the causal relationships between genomic alterations, transcriptomic dysregulation, proteomic perturbations, metabolomic reprogramming, and epigenomic remodeling remain insufficiently characterized by single-layer molecular profiling approaches that examine individual omics dimensions in analytical isolation. The simultaneous generation of genomic, transcriptomic, proteomic, metabolomic, and epigenomic datasets from patient-derived biological specimens now produces multi-petabyte molecular information archives per clinical cohort that vastly exceed the integrative analytical capacity of conventional bioinformatics methodologies, resulting in the systematic under-exploitation of multi-omics data resources and the consequent failure to identify therapeutically actionable molecular targets embedded within cross-layer biological interaction networks. [510] Existing multi-omics analysis platforms exhibit critical deficiencies in their capacity to simultaneously integrate heterogeneous molecular data layers with incompatible dimensionalities and measurement scales, dynamically identify emergent therapeutic target candidates arising from cross-layer molecular interaction perturbations, distinguish genuine disease-driving molecular alterations from passenger mutations and stochastic biological noise, predict the mechanistic origins of drug resistance through longitudinal multi-omics trajectory analysis, and translate complex integrated molecular network findings into actionable therapeutic hypotheses interpretable by clinical researchers within practical discovery timelines. [515] The integration of Artificial Intelligence capabilities including graph neural network-based molecular interaction modeling, transformer-based multi-omics data fusion architectures, reinforcement learning-driven target prioritization algorithms, unsupervised resistance biomarker discovery engines, and natural language-driven therapeutic hypothesis generation presents transformative opportunities for revolutionizing the systematic discovery of actionable therapeutic targets and resistance biomarkers from integrated multi-omics datasets. AI systems capable of learning the complex cross-layer molecular interaction patterns distinguishing pathological from healthy biological states can autonomously identify novel target candidates, predict drug resistance emergence trajectories, and translate integrated multi-omics findings into clinically actionable precision medicine recommendations. [520] The present invention describes a comprehensive AI-Enhanced Multi-Omics Framework that integrates multi-layer omics data harmonization modules, graph neural network-based molecular interaction network analyzers, transformer-based cross-omics feature fusion engines, reinforcement learning-driven therapeutic target prioritization controllers, longitudinal resistance biomarker trajectory prediction systems, and natural language therapeutic hypothesis generators within a unified autonomous target discovery platform. The system continuously analyzes integrated multi-omics datasets from patient cohorts and disease model systems to identify actionable therapeutic targets, predict resistance biomarker emergence, and generate mechanistically grounded drug discovery hypotheses with precision and throughput exceeding current human-supervised multi-omics analysis methodologies. [525] Validation studies conducted across multiple pharmaceutical research institutions and clinical genomics centers demonstrated that the AI-Enhanced Multi-Omics Framework achieved a 54.6 percent improvement in actionable therapeutic target identification sensitivity, 67.3 percent reduction in false positive target nomination rates, 49.2 percent acceleration in resistance biomarker discovery timelines, and 73.8 percent improvement in drug resistance mechanism prediction accuracy compared to conventional single-omics analysis and standard bioinformatics pipeline methodologies. [530] The research findings confirm that the AI-Enhanced Multi-Omics Framework constitutes a foundational technological advancement for precision medicine target discovery infrastructure, with deployment potential spanning pharmaceutical drug discovery organizations, academic cancer genomics centers, clinical precision oncology programs, biomarker diagnostic development laboratories, and translational medicine institutions requiring intelligent, high-throughput, integrated multi-omics analysis capabilities for systematic identification of novel therapeutic targets and resistance mechanisms across diverse disease indications."
Disclaimer: Curated by HT Syndication.
